A Phase III Randomized, Open-Labeled Clinical Trial of MK3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-Sided Infective Endocarditis Caused by MRSA.

Trial Profile

A Phase III Randomized, Open-Labeled Clinical Trial of MK3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-Sided Infective Endocarditis Caused by MRSA.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Daptomycin (Primary) ; Vancomycin
  • Indications Bacterial endocarditis; Methicillin-resistant Staphylococcus aureus infections; Septicaemia; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 27 Sep 2011 Treatment table and purpose added.
    • 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 07 Apr 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top